Navigation Links
Kidney Care Community Voices Strong Support for Kidney Patients' Right to Choose
Date:10/22/2007

House of Representatives' Extension of Medicare Secondary Payer (MSP) for Kidney Dialysis Patients Praised for Providing Clinical, Economic and Family Benefits for Patients

WASHINGTON, Oct. 22 /PRNewswire-USNewswire/ -- In response to the House-passed Children's Health and Medicare Protection (CHAMP) Act of 2007 provision to extend Medicare Secondary Payer (MSP) in the End Stage Renal Disease (ESRD) program for patients who rely on dialysis care, Kidney Care Partners (KCP)-- an alliance of patient advocates, dialysis professionals, care providers and manufacturers working together to improve quality of care for individuals with kidney disease and kidney failure --strongly endorses extending patients' right to remain with their commercial coverage for an additional 12 months - a total of 42 months. KCP believes that the additional 12 months strikes the correct balance between the current law of 30 months and proposed extensions of up to 60 months.

Under the current Medicare MSP provision, Medicare takes over as primary coverage after 30 months. The CHAMP act would extend the MSP provision an additional 12 months for patients within large health plans - those plans defined as having more than 100 employees. This extension would benefit approximately 10,000 out of the more than 400,000 Medicare ESRD patients and would have a negligible impact on large employer premiums.

"Despite what some large corporations are saying, this extension impacts a modest number of patients spread across a much larger population and would be a huge benefit to patients and the Medicare benefit," said Dr. Edward Jones, a practicing nephrologist and Chairman of KCP. "A 12 month extension of the MSP provision gives some patients with private insurance a choice in their healthcare coverage. Further, KCP believes that extending this provision by 12 months will encourage large health plans to focus more heavily on disease prevention, address co-morbidities and encourage
'/>"/>

SOURCE Kidney Care Partners
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Is Diabetes the Leading Cause of Kidney Failure in India
2. Kidney Stones - Interesting New Research implicates bacteria as its cause
3. Moderate Use of Analgesics - Not Associated With Kidney Dysfunction
4. Early test to detect kidney failure
5. Angiotensin-II-receptor blockers - Treat kidney failure
6. Helping the neurology of kidney failure
7. Woman gets cancer from transplanted kidney
8. New Dietary Approach To Manage Kidney Stones
9. Diet plays a role in kidney stones
10. Kidney cancer on the rise
11. Vitamin E decreases high blood pressure in kidney failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...Va., Nov. 21 New resear...her a smokeless, spitless tobacco product aimed at...have found that RJ Reynolds, Camel Snus - touted a... contains surprisingly high levels of nicotine. ,...ost other snuff products," said Bruce Adkins of th...
(Date:11/21/2008)...ders Intend To Vigorously Protect Investment And R...v. 21 Dr. Stephen Joffe...dment to their Schedule 13D with the U.S. Securiti...filed a 13D disclosing ownership of 11.4% of LCA-V...asikPlus fixed-site laser vision correction center...
(Date:11/21/2008)... 21 The general membership of the ...three new individuals at their Annual,Awards Dinn...l in New York. A,Lifetime Achievement Award will ...e Medical Advertising Hall of Fame are: , Ronal...an account position,at Sudler & Hennessey. In...
(Date:11/21/2008)..., Nov. 21 Barr Pharmaceu...ts shareholders overwhelmingly approved the propos...of Barr by Teva Pharmaceuticals Industries Ltd. (N...rated the overwhelming support of the transaction ...arr,s Chairman and CEO. "We are pleased with the p...
Breaking Medicine News(10 mins):Health News:Experts Say New Tobacco Product Targets Young Adults 2Health News:Experts Say New Tobacco Product Targets Young Adults 3Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 3Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 4Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 5Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 6Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 7Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 2Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 3Health News:Barr Shareholders Approve Pending Teva Acquisition 2Health News:Barr Shareholders Approve Pending Teva Acquisition 3Health News:Barr Shareholders Approve Pending Teva Acquisition 4
...es virus that causes infectious mononucleosis, Eps...ntribute to the development of Hodgkin's disease. ... between EBV and Hodgkin's survival, according to ... A. Clarke from Northern California Cancer Center ...
...C and the British Scientific journal Human Reprodu... scientists has successfully altered the genetic m...he scientists who developed the technique in the U... children had been born with altered genes.However...
...h scientists have started exploring possibilities ...nt need indole acetic acid to bend shoots toward s... the Cancer Research Campaign (CRC), a leading sci...ments to IAA to kill cancer cells. Indole ace...
...s of two new studies suggest that low-dose estroge...t for women experiencing menopausal hot flushes an...ity says low-dose estrogen therapy is as effective...pausal symptoms. Low-doses are actually are more e...
Other Medicine News:
(Date:11/20/2008)...Nov. 20 New Jersey American Water ... for its customers in the following municipalities..., Middlesex County , , , Dunelle...ataway , South Plainfield , , , ...rook , Bridgewater , Green Brook , ...
(Date:11/20/2008)... Nov. 20 Bionovo, Inc.,...nt results from the Phase 1B,clinical trial of th...east,cancer, BZL101, at the Society for Integrati...tlanta, Georgia. The Company,s oral presentation ...e presented as a part of the Best of the,SIO Sess...
(Date:11/20/2008)... November 20 The Scandinavian-base...nounced results of studies on its,lead antimicrob...ngton, DC,the studies showed that the novel lyti... effect, significantly better towards killing Stap... marketed gold standard drugs. In,addition to thi...
(Date:11/19/2008)... Nov. 19 Biotech scientists increa...ology research to better understand the effects of...ms, reports Genetic Engineering & Biotechnolo...n figuring out a new compound,s mechanism of actio...y technique, according to the November 15 issue of...
Breaking Medicine Technology:New Jersey American Water Lifts Precautionary Boil Water Advisory For Middlesex, Somerset and Union Counties 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2GEN Reports on the Trend Toward Predictive Toxicogenomics 2Take Care Health Systems Names Butler Shine Stern 26 Partners as First Marketing Agency of Record 14322 1Take Care Health Systems Names Butler Shine Stern 26 Partners as First Marketing Agency of Record 14322 2Take Care Health Systems Names Butler Shine Stern 26 Partners as First Marketing Agency of Record 14322 3New research provides dynamic visualization of simplest circadian clock 14321 1New research provides dynamic visualization of simplest circadian clock 14321 2All eyes and ears on the corn genome 2496 1All eyes and ears on the corn genome 2496 2All eyes and ears on the corn genome 2496 3Study in Circulation Research details how diabetes drives atherosclerosis 14319 1Study in Circulation Research details how diabetes drives atherosclerosis 14319 2Study in Circulation Research details how diabetes drives atherosclerosis 14319 3
... 15 /CNW/ - Today AMADEO, one of the,first studies...tensin receptor blockers in hypertensive patients...uropean Society,of Hypertension, Milan. The resul...proteinuria to a significantly greater extent,than... Prof. Ellen Burgess, Foothills Hospital,in Calga...
... 2007 /PRNewswire-FirstCall/ -- Anadys,Pharmaceuti... to,the discovery, development and commercializati...is and cancer, announced today that it,has nominat...as an,orally-administered direct antiviral for the...ction. , "We have identified a small-molecule, non...
Other Medicine Technology:New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes 2New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes 3New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes 4New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes 5Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection 2Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection 3Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection 4
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
Medicine Products: